Indications › Diabetic kidney disease
GLP‑1 drugs in diabetic kidney disease
Which incretin agents are being studied in diabetic kidney disease, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.
- Trials on file
- 9
- Active
- 3
- Results scheduled
- 0
- Molecules studied
- 5
- Sponsors
- 8
No GLP‑1 or incretin drug is FDA-approved for diabetic kidney disease. The trials below are studies, not approvals, and most drugs tested in a new condition never get approved for it.
No GLP-1 or incretin drug is approved for diabetic kidney disease, so everything below is investigational. Most drugs tested in a new condition never reach approval for it, and a registration is not evidence of benefit. 7 of the 9 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 2 still in early phases. 8 distinct sponsors are involved.
Molecules studied in this indication
dulaglutide · liraglutide · lixisenatide · mazdutide · semaglutide
Trials on file
All 9 incretin trials recorded in this indication, active first.